Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 331.13B | 332.59B | 303.92B | 338.57B | 344.05B |
Gross Profit | 127.67B | 120.35B | 110.75B | 158.03B | 162.41B |
EBITDA | 29.06B | 32.54B | 27.93B | 35.09B | 34.36B |
Net Income | 8.11B | 14.13B | 8.10B | 13.52B | 11.84B |
Balance Sheet | |||||
Total Assets | 377.77B | 395.74B | 369.05B | 356.74B | 340.08B |
Cash, Cash Equivalents and Short-Term Investments | 60.24B | 97.20B | 91.93B | 102.25B | 98.64B |
Total Debt | 165.00M | 30.00B | 30.02B | 30.35B | 30.64B |
Total Liabilities | 105.18B | 132.63B | 124.30B | 115.57B | 117.53B |
Stockholders Equity | 272.00B | 262.54B | 244.29B | 240.79B | 221.75B |
Cash Flow | |||||
Free Cash Flow | -15.66B | 9.69B | -8.89B | 4.89B | 474.00M |
Operating Cash Flow | 1.81B | 28.06B | 16.80B | 28.65B | 17.22B |
Investing Cash Flow | -10.26B | -10.37B | -20.14B | -29.19B | -12.44B |
Financing Cash Flow | -39.15B | -6.09B | -10.28B | -4.86B | -9.74B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | ¥306.17B | 11.49 | 10.59% | 2.87% | 4.55% | 14.94% | |
73 Outperform | ¥293.16B | 18.99 | 4.16% | 8.96% | 9.34% | ||
73 Outperform | $353.92B | 19.74 | 8.89% | 2.11% | 6.38% | -16.25% | |
69 Neutral | ¥259.42B | 20.26 | 1.95% | 11.08% | -46.09% | ||
68 Neutral | ¥221.80B | 22.29 | 8.23% | 2.16% | 4.86% | -0.10% | |
60 Neutral | ¥286.96B | 38.52 | 2.78% | 2.97% | -46.46% | ||
58 Neutral | ¥316.12B | 37.86 | 3.19% | 1.85% | 2.44% | -18.02% |
Ezaki Glico Co., Ltd. announced the establishment of a special purpose company, Glico Europe B.V., in the Netherlands as part of its strategy to pursue global growth investments. This move aligns with the company’s mid-term management plan to expand its business into new areas and promote global growth, with a minor expected impact on the company’s earnings for the fiscal year ending December 31, 2025.